Related Experiment Videos
A new agent for the control of spasticity
Journal of Neurology, Neurosurgery, and Psychiatry
|August 1, 1970
Summary
CIBA 34,647-Ba, a gamma aminobutyric acid derivative, effectively reduced spasticity in spinal injuries. This new treatment showed promise compared to placebo and diazepam with no significant side-effects observed.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Spasticity is a common and debilitating symptom following spinal cord injuries.
- Current treatments for spasticity, such as diazepam, can have significant side effects.
- There is a need for novel therapeutic agents to manage spinal spasticity.
Purpose of the Study:
- To evaluate the efficacy of CIBA 34,647-Ba, a gamma aminobutyric acid derivative, in reducing spasticity.
- To compare the effectiveness of CIBA 34,647-Ba against placebo and diazepam.
- To assess the safety and side effect profile of CIBA 34,647-Ba.
Main Methods:
- A preliminary controlled trial comparing CIBA 34,647-Ba to placebo.
- An uncontrolled trial comparing CIBA 34,647-Ba to diazepam.
- Electromyography was used to measure stretch reflex amplitude, correlated with clinical assessments.
Main Results:
- CIBA 34,647-Ba demonstrated superior efficacy over placebo in reducing spasticity.
- In an uncontrolled setting, CIBA 34,647-Ba appeared more effective than diazepam.
- The drug was effective in both complete and incomplete spinal cord lesions.
Conclusions:
- CIBA 34,647-Ba shows significant potential as a treatment for spasticity resulting from spinal injuries.
- The compound appears to act at the spinal level.
- No significant adverse events were reported, suggesting a favorable safety profile.